Table 1.
Clinical Characteristics of Patients Analyzed for SMARCA4 from the Director’s Challenge Study & JBR.10 Trial
| Director’s Challenge Study SMARCA4 Expression | JBR.10 SMARCA4 Expression | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Clinical Factor | Low | Int | High | P-value | Clinical Factor | Low | High | P-value |
| Age | 0.52 | Age | 0.76 | |||||
| <=65 (n=230) | 66 (29%) | 100 (43%) | 64 (28%) | <=65 (n=87) | 44 (51%) | 43 (49%) | ||
| >65 (n=210) | 70 (33%) | 82 (39%) | 58 (28%) | >65 (n=66) | 22 (48%) | 24 (52%) | ||
|
| ||||||||
| Gender | 0.02 | Gender | 0.42 | |||||
| Female (n=219) | 57 (26%) | 90 (41%) | 72 (33%) | Female (n=42) | 23 (55%) | 19 (45%) | ||
| Male (n=221) | 79 (36%) | 92 (42%) | 50 (22%) | Male (n=91) | 43 (47%) | 48 (53%) | ||
|
| ||||||||
| Treatment | 0.19 | Treatment | 0.78 | |||||
| Adjuvant treatment (n=45) | 17 (38%) | 20 (44%) | 8 (18%) | Adjuvant treatment (n=71) | 36 (51%) | 35 (49%) | ||
| No Adjuvant treatment (n=213) | 60 (28%) | 97 (46%) | 56 (26%) | No adjuvant treatment (n=62) | 30 (48%) | 32 (52%) | ||
|
| ||||||||
| Stage | 0.46 | Stage | 0.53 | |||||
| IA (n=113) | 33 (29%) | 48 (42%) | 32 (28%) | |||||
| IB (n=162) | 49 (30%) | 67 (41%) | 46 (29%) | IB (n=73) | 38 (52%) | 35 (48%) | ||
| IIA+IIB (n=94) | 26 (28%) | 39 (41%) | 29 (31%) | IIA+IIB (n=60) | 28 (47%) | 32 (53%) | ||
| IIIA+IIIB (n=68) | 28 (41%) | 26 (38%) | 14 (21%) | |||||
|
| ||||||||
| Histology | Histology | 0.22 | ||||||
| ADC (n=440) | 136 (31%) | 182 (41%) | 122 (28%) |
ADC (n=71) SQCC (n=52) LCUC (n=10) |
40 (56.3%) 21 (40.4%) 5 (50%) |
31 (43.7%) 31 (59.6%) 5 (50%) |
||
*
P-values were calculated using Χ2 Test
The probe sets that were the most statistically significant in correlation with clinical outcomes are shown for each study. Probe set 212520_s_at was used for the Director’s Challenge Study and probe set (213719_s_at) was used for the JBR.10 study.
ADC = adenocarcinoma, SQCC = squamous cell carcinoma, LCUC = large cell carcinoma